3/21/2011 8:08:43 AM
SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)--Specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced new data on 62 patients with Hereditary Angioedema (HAE) who received repeat treatment with the investigational drug RHUCIN® (recombinant human C1 inhibitor) for 168 acute angioedema attacks. The median time to beginning of relief of symptoms across treatments for repeat attacks was approximately 60 minutes with response rates that were consistently 90% or greater. This open-label study was an extension of the randomized, double-blind, placebo-controlled study conducted by Pharming in North America. The findings were presented Sunday, March 20, 2011 in a poster session at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2011 Annual Meeting in San Francisco.
comments powered by